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Abstract
Background: Silence of the tumor suppressor miR-34c is implicated in the development of colorectal cancer (CRC).
For the past few years, Resveratrol (Res) has been introduced to oncotherapies alone or with traditional
chemotherapeutic drugs. However, the study of molecular mechanism involved in the anti-CRC effect of Res is still
ongoing.
Methods: The anti-CRC effect of Res alone or with Oxaliplatin (Oxa) was determined by cell viability assay, soft agar
colony formation assay, flow cytometry and real-time cellular analyzer in HT-29 (p53+) and HCT-116 (p53−) CRC cell
lines. Expressions of miR-34c and its targets were detected by qPCR and/or western blot. To evaluate the role of
miR-34c in anti-CRC effect by Res alone or with Oxa, miR-34c was up or down-regulated by lentiviral mediation or
specific inhibitor, respectively. To investigate how miR-34c was increased by Res, the methylation status of miR-34c
promoter was detected by MSP. The tumor bearing mouse model was established by subcutaneous injection of
HCT-116 cells to assess anti-CRC effect of Res alone or with Oxa in vivo. IL-6 and TNF-α in xenografts were detected
by ELISA.
Results: Res inhibited cell viability, proliferation, migration and invasion as well as promoted apoptosis both in HT-
29 and HCT-116 CRC cells. The anti-CRC effect of Res was partially but specifically through up-regulating miR-34c
which further knocked down its target KITLG; and the effect was enhanced in the presence of p53 probably
through inactivating PI3K/Akt pathway. Besides, Res sensitized CRC cells to Oxa in a miR-34c dependent manner.
The xenograft experiments showed that exposure to Res or Oxa suppressed tumor growth; and the efficacy was
evidently augmented by the co-treatment of Res and Oxa. Likewise, miR-34c level was elevated in xenografts of
Res-treated mice while the KITLG was decreased. Finally, Res clearly reduced IL-6 in xenografts.
Conclusion: Res suppressed CRC by specifically activating miR-34c-KITLG in vitro and in vivo; and the effect was
strengthened in the presence of p53. Besides, Res exerted a synergistic effect with Oxa in a miR-34c dependent
manner. We also suggested that Res-increased miR-34c could interfere IL-6-triggered CRC progression.
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Background
The incidence and mortality of colorectal cancer (CRC)
rank the top 5 among all malignant neoplasms both in
China and western countries. Except for exairesis,
chemotherapy is one of the most common treatments
for CRC patients, especially those who have distant
metastasis. However, long-term use of chemotherapeu-
tic drugs e.g. oxaliplatin (Oxa) can cause several side
effects such as hepatotoxicity and neurotoxicity and
induce drug resistance [1–3]; thus, it is hard to achieve
the expectations. Nowadays, several natural compounds
have been introduced in anti-tumor researches and
clinical oncotherapies, either alone or combined with
traditional chemotherapeutic drugs. Resveratrol (Res) is
a natural polyphenolic compound rich in peanuts, red
wine and grapes. Apart from the well-documented anti-
inflammation and anti-oxidation effects [4, 5], Res has
an anti-tumor potential in CRC and other cancers in
vitro and in vivo [6–9], excitingly, without apparent
side effects.
Efforts have been made to figure out how Res plays the
anti-tumor role, which is of importance for the better
application of Res in clinic. It has been reported that Res
could induce cell apoptosis and cell cycle arrest via p53
pathway and/or caspase/cyclin-CDK pathway to achieve
its anti-tumor activities [10, 11]. Identification of the role
that microRNAs play in human cancer pathogenesis trig-
gered researches in the regulation of Res on microRNA
expressions. Depending on their targets, microRNAs
could serve as either oncogenes or tumor suppressing
genes. Accumulating evidence showed that Res decreased
miR-520 h and subsequently suppressed tumor cell inva-
sion and migration in lung cancer cells [12]. Res also
inhibited cancer growth and metastasis of SW480 human
CRC cells by inducing miR-663 expression [13]. These
observations clearly indicated that microRNAs were in-
volved in the Res-mediated anti-tumor activities.
MiR-34c is suggested to be a candidate of tumor sup-
pressing gene and epigenetically silenced in CRC [14, 15].
We recently found that over-expression of miR-34c in-
duced apoptosis and inhibited proliferation and invasion
in CRC cells by silencing its target, stem cell factor (SCF,
also known as KITLG) [16], suggesting miR-34c as a
promising target for the treatment of CRC patients. Be-
sides, it has been recently raised that Res inhibited human
CRC cell growth and induced apoptosis through up-
regulating miR-34a, a homologue of miR-34c, imply-
ing a possible similar modulation of Res on miR-34c
expression [17]. However, whether miR-34c is impli-
cated in the Res-mediated anti-CRC effect has not yet
been fully elucidated. Furthermore, how Res syner-
gizes with Oxa in the treatment of CRC needs clari-
fied besides its protection from the Oxa-induced
hepatotoxicity and neurotoxicity [18].
In the present study, we provided evidence that Res
itself could not only exert significant anti-CRC effect,
but also showed a synergistic effect with Oxa in a miR-
34c dependent manner.
Methods
Cell culture and reagents
Human CRC cell lines HT-29 (p53+) and HCT-116 (p53−)
were purchased from the Cell Bank of Chinese Academy
of Sciences. All cell lines were cultured in DMEM
medium (Life Technologies, USA) supplemented with
10 % fetal bovine serum (Life Technologies) and 1 % peni-
cillin/streptomycin (Life Technologies). Cells were grown
at 37 °C in the presence of 5 % CO2 and treated with Res
(Sigma, USA) and/or Oxa (Sigma). DMSO (Sigma) was
used as control.
Cell viability assay
Cell viability was detected by cell counting kit-8 (CCK-8,
Dojindo Laboratories, Japan) according to the manufac-
turer’s protocol. Cells were seeded in 96-well plates at
3 × 103 cells per well. 10 μL of the tetrazolium substrate
was added to each well. The plates were incubated at
37 °C for 1 h and the absorbance was measured at
450 nm using Multiskan FC (Thermo Scientific, USA).
All experiments were done in triplicate and repeated
three independent times.
Combination Index (CI) calculation
To assess the drug interactions of Res and Oxa, the CI
value defined by median-effect analysis was calculated as
follows:
CI ¼ DXð ÞRes= Dð ÞRes þ DXð ÞOxa= Dð ÞOxa
where (D)Res and (D)Oxa are the doses for each drug
alone that inhibits 50 % cell viability, and (DX)Res and
(DX)Oxa are the doses for Res and Oxa in a combination
that inhibits 50 % cell viability. CI < 1 indicates a syner-
gistic effect; CI = 1, additive effect; and CI > 1, antagonis-
tic effect [19].
Soft agar colony formation assay
The bottom of 6-well plate was coated with 0.6 % low
melting agarose (Promega, USA) and covered with
0.35 % agarose containing 1000 cells. The plates were in-
cubated at standard incubator condition for 2 weeks.
Colonies were counted under inverted phase contrast
microscope (Leica DMI3000 B, Germany) in 9 randomly
sampled visual fields each well by stereological tech-
nique. All experiments were done in triplicate.
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Western blot
The harvested cells were suspended in RIPA (Radio-
Immunoprecipitation Assay) lysis buffer (Applygen,
Beijing, China). After 10 % SDS-PAGE, the proteins
were transferred onto PVDF membrane (Merk-Millipore,
USA) and blocked with 5 % non-fat dry milk or 5 % bo-
vine serum albumin (Sigma) for 1 h. The membrane was
incubated with rabbit anti-KITLG (1:500, Abcam, UK),
mouse anti-p53 (1:1000, Cell Signaling Technology, USA),
rabbit anti-Akt (1:1000, Cell Signaling Technology) or
rabbit anti-p-Akt (1:2000, Cell Signaling Technology) pri-
mary antibody at 4 °C overnight. Then, the membrane
was incubated with HRP-conjugated secondary goat anti-
mouse IgG (1:2000, Santa Cruz, USA) or goat anti-rabbit
IgG (1:2000, Santa Cruz) for 1 h at 25 °C. The proteins
were detected using ECL chemiluminescence (Thermo
Scientific) and viewed in Fusion FX Vilber Lourmat
(France). A mouse anti-actin (1:4000, Santa Cruz) anti-
body was used as an internal control.
Real-time monitoring of cellular proliferation, migration
and invasion
We employed real-time cellular analyzer (RTCA, ACEA
Biosciences, USA) to monitor cellular proliferation, mi-
gration and invasion as we previously described [16].
Briefly, for the proliferation assay, the cells were seeded
in E-plates at a density of 8000 cells/well and the cell
index (CI) was automatically recorded every 15 min. For
the migration assay, the cells were seeded in the upper
chambers of CIM-plates in serum-free medium at a
density of 20,000 cells/well. The bottom chambers of
CIM-plates were filled with serum-containing medium
to promote migration across the membranes towards
the serum gradient. The CI was registered only from the
cells that were capable of migrating through the mem-
branes. The protocol for the invasion assay was identical
to that for the migration assay, except that the upper
chambers were loaded with 30 μl of 5 % Matrigel (BD
Biosciences, USA) solution to create a 3D biomatrix film
in each well prior to cell seeding. Four independent
experiments were performed respectively. The slope of
CI curve was analyzed.
RNA extraction and qPCR
The total microRNA was extracted using miRNApure
Mini Kit (CWBiotech, Beijing), according to the manufac-
turer’s instruction. Reverse transcription was performed
using Taqman microRNA RT Kit (Life Technologies) and
Taqman microRNA Assay with specific stem-loop
primers. Real-time PCR was performed using Taqman
Universal Master Mix II (Life Technologies). The reac-
tions were incubated at 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s and 60 °C for 1 min in ABI
7500 real-time PCR system. Results were normalized to
the internal control, RNU6B.
The total RNA was extracted using TRIzol reagent (Life
Technologies) according to the manufacturer’s instruction.
Reverse transcription reactions were performed using
High Capacity RNA-to-cDNA Kit (Life Technologies).
Real-time PCR was performed in ABI 7500 real-time PCR
system using SYBR Green PCR Master Mix (Life
Technologies). The primers are listed in Table 1. The reac-
tions were incubated at 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s and 60 °C for 1 min.
All reverse transcription reactions included no-
template controls, and all PCR reactions were run in
triplicates. Relative microRNA or mRNA expression was
determined using the comparative CT (2
-ΔΔCt) method.
Flow cytometry
For cell apoptosis analysis, AlexaFluor® 488 Annexin V/
Dead Cell Apoptosis Kit (Life Technologies) was used ac-
cording to the manufacturer’s instruction. In Brief, cells
were seeded in 6-well plates and 1 × 105 cells were resus-
pended in annexin binding buffer, after which annexin V
and propidium iodide (PI, 100 μg/mL) were added and in-
cubated at 25 °C for 15 min in the dark. Cell apoptosis
was analyzed in Coulter EPLCS XL (Beckman Coulter,
USA). All experiments were done in triplicate.
For cell cycle analysis, 1 × 106 cells were fixed with 70 %
ethanol for 2 h at 4 °C, followed by the treatment with
phosphate buffered saline containing RNase (50 μg/mL)
for 30 min at 37 °C. Cells were stained with PI (500 μg/
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analyzed by measuring the DNA contents in Coulter
EPLCS XL. All experiments were done in triplicate.
Over-expression of miR-34c by lentiviral mediation
The full length of pre-miR-34c was chemically synthesized
and introduced into GV217 lentiviral vector (GeneChem,
Shanghai, China) in the unique EcoRI site to construct a
lentivirus encoding miR-34c (Lv-miR-34c). The Lv-miR-
34c or its control, Lv-NC, was transfected into CRC cells
seeded in 6-well plates when reaching 30 % confluence.
After 3 days, the infectious efficiency was evaluated by
observing the EGFP-expression with an inverted phase
contrast microscope (Leica DMI3000 B, Germany).
MiR-34c knockdown
For knockdown of miR-34c, the specific miR-34c inhibitor
was purchased from Ribobio (Guangzhou, China). The
inhibitor or its control, inhibitor-NC, was transfected into
CRC cells using riboFECT™ CP Transfection Kit (Ribobio)
according to the manufacturer’s instruction.
Methylation Specific PCR (MSP)
The genomic DNA of CRC cells was extracted using
QIAamp® DNA Mini Kit (Qiagen, USA). 200 ~ 500 ng
DNA was subject to bisulfite conversion using EZ DNA
Methylation-Gold™ Kit (Zymo Research, USA). The
methylation-sensitive PCR was performed using Plat-
inum Taq DNA Polymerase (Life Technologies). The
PCR reaction conditions consisted of an initial incuba-
tion at 94 °C for 2 min, followed by 35 cycles of 94 °C
for 30 s, 55 °C for 30 s and 68 °C for 1 min using verity
96-well thermo cycler (Applied Biosystems). The primers
are listed in Table 1. The PCR products were electropho-
resed in 0.75 % agarose gel, and visualized by uitraviolet
illumination.
Xenograft in BALB/c nude mouse
In order to determine the in vivo anti-CRC effect of Res,
the CRC cell xenograft in BALB/c athymic nude mice
(3–4 weeks old) were performed. Twenty-eight nude
mice were purchased from the Experimental Animal
Center in the Capital Medical University and housed
under Specific Pathogen Free condition. 5 × 106 HCT-
116 cells suspended in 50 μL phosphate buffered saline
were subcutaneously injected into the right armpit of
the nude mice. Ten days after cell xenograft, the nude
mice were randomly grouped (7 mice/group) and
received Res (100 mg/kg), Oxa (10 mg/kg), Res (100 mg/
kg) + Oxa (10 mg/kg) or DMSO via tail-vein injection
every day for 2 weeks based on modification of previous
report [18]. The body weight and tumor size were mea-
sured every other day. The tumor volume was calculated
as: W2 × (L/2), where W represents the tumor width and
L the tumor length. The experimental procedures were
approved by the Institutional Review Board of the
Capital Medical University.
ELISA
The xenografts were lyzed; and the supernatants from
xenografts as well as the serum of mice were collected.
The concentrations of IL-6 and TNF-α was determined
by ELISA according to the manufacturer’s instructions
(R&D Systems, USA). The absorbance of each well at
490 nm was read using the microplate reader (Multiskan
FC, Thermo Scientific). All experiments were done in
triplicates.
Statistics analysis
All statistical analysis were performed using SPSS 13.0
(Chicago, USA). Values are expressed as means ± SEM.
Results were analyzed by Student’s t test or one-way
ANOVA. The P value < 0.05 was considered to be statis-
tically significant.
Results
In vitro anti-CRC effect of Res
Cell viability was significantly reduced after 24 h-treat-
ment with Res in a dose dependent manner (P < 0.01 ~
0.001, Fig. 1a). Based on the results, we used 100 μM
Res for HT-29 cells and 50 μM Res for HCT-116 cells
in the following experiments. Importantly, it has been
delineated that Res derivatives had no effect on non-
tumor cells (IEC18 intestinal epithelium cells) [20]. By
real-time monitoring in RTCA we found that Res
decreased cell proliferation by 45.9 % in HT-29 cells (P
< 0.05) and 57.4 % in HCT-116 cells (P < 0.05) (Fig. 1b).
To find out the mechanism of the Res-induced prolifer-
ative suppression, we detected the cell cycle by flow
cytometry. HCT-116 cells arrested in G0/G1 phase
were elevated by 54.4 % (P < 0.001) after treated with
Res, and the percentage of G2/M phase HT-29 cells
were elevated by 37.1 % (P < 0.001) (Fig. 1c, Additional
file 1: Figure S1), indicating that Res inhibited the
proliferation of CRC cells by arresting cell cycle. Res as
well increased apoptosis in HT-29 cells by 38.6 % (P <
0.01) and in HCT-116 cells by 45.5 % (P < 0.01) (Fig. 1d,
Additional file 2: Figure S2). Effect of Res on the malig-
nant transformation of CRC cells was examined by soft
agar colony formation assay. The number and size of
colonies in the Res-treated HCT-116 and HT-29 cells
were obviously reduced compared with those in con-
trols (P < 0.001, Fig. 1e). Besides, Res significantly sup-
pressed cell migration by 42.2 %, (P < 0.01) and
invasion by 51.1 % (P < 0.01) of HCT-116 cells observed
by RTCA (Fig. 1f ).
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Anti-CRC effect of Res is partially through activating miR-
34c-KITLG axis
MicroRNAs emerge as potent regulators of numerous
oncogenes and anti-oncogenes. We then asked whether
the anti-CRC role of Res could be through microRNAs.
We selected tumor suppressing microRNA, miR-34c
which we have previously reported [16], to investigate
the potential anti-CRC mechanism of Res. After expos-
ure to Res for 24 h, miR-34c was strikingly increased 5.4
folds (P < 0.01) in HCT-116 cells and 19.2 folds (P <
0.01) in HT-29 cells (Fig. 2a), while KITLG, a target of
miR-34c [16], was evidently decreased in these CRC cells
(P < 0.05, Fig. 2b). To consolidate the role of miR-34c in
the Res-mediated anti-CRC activity, we knocked down
miR-34c in HCT-116 cells by its specific inhibitor
(Fig. 2c). The inhibitory effect of Res on KITLG expres-
sion was abolished when silencing the endogenous miR-
34c (P < 0.05, Fig. 2d). Interestingly, accompanied with
the reduced miR-34c the anti-CRC effect of Res were at-
tenuated. The Res-suppressed cell proliferation, migra-
tion and invasion were recovered by 14.6% (P < 0.05),
11.9% (P < 0.05) and 49.3% (P < 0.01) respectively in
HCT-116 cells in the presence of miR-34c inhibitor
(Fig. 2e). Moreover, we detected some other documented
oncogenic microRNAs including miR-9 and miR-19a,
and tumor suppressing microRNAs including miR-28,
miR-33a, miR-34a and miR-214, as well as their targets
E-cadherin, PTEN, HoxB3, Pim, KIT and FGFR1, re-
spectively [21–26], to figure out the Res-induced micro-
RNA expression profile. Results showed that despite Res
induced miR-28 and miR-34a (P < 0.01, Fig. 2g), their
respective targets HoxB3 and KIT were not decreased
during Res treatment (Fig. 2g), suggesting that Res prob-
ably had a specific effect on miR-34c-KITLG axis in
CRC cells. Collectively, these results demonstrated that
the anti-CRC effect of Res could be partially through
activating the miR-34c-KITLG axis.
Upregulation of miR-34c by Res is not through
demethylation but p53 related
It is well accepted that the promoter of miR-34c is
hypermethylated in CRC tissues and cell lines, which
lead to silencing of miR-34c [27]. So we carried out MSP
to investigate whether the Res-induced miR-34c in CRC
Fig. 1 a Twenty-four hr-Res treatment significantly reduced CRC cell viability detected with CCK8 in a dose-dependent manner (12.5 ~ 400 μМ).
** P < 0.01, *** P < 0.001 (b) CRC cell growth was monitored by RTCA for 48 h in the presence of Res or DMSO. Cells treated with Res displayed
lower proliferation. c Res induced cell cycle arrest in HT-29 cells (G2/M phase) and HCT-116 cells (G0/G1 phase) analyzed by flow cytometric
analysis. *** P < 0.001 (d) Res increased cell apoptosis in CRC cells analyzed by flow cytometric analysis. ** P < 0.01 (e) Soft agar colony formation
assay showed that the size and number of colonies in Res-treated CRC cells were reduced. *** P < 0.001 (f) Res inhibited the migratory and
invasive capacities of HCT-116 cells monitored by RTCA
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cells could be resulted from demethylation of the miR-
34c promoter. Unfortunately, we did not find apparent
demethylation upon the treatment of Res for 24 h, 48 h
or 72 h, indicating the upregulation of miR-34c by Res
was not through inducing demethylation of the miR-34c
promoter (Fig. 3a).
MiR-34c transcription is under the control of p53
which is hypoexpressed in CRC tissues and cell lines
[27]. Could p53 be involved in the Res-induced miR-34c
in CRC cells? We used p53+ and p53− CRC cells and
found elevated miR-34c in both CRC cell lines, indicat-
ing that Res regulated miR-34c in a p53 independent
Fig. 2 a Res increased miR-34c in CRC cells, which was more prominent in p53+ HT-29 cells than in p53− HCT-116 cells. ** P < 0.01 (b) KITLG, the
target of miR-34c, was significantly decreased at mRNA and protein levels upon the treatment of Res. * P < 0.05, ** P < 0.01 (c) MiR-34c inhibitor
efficiently knocked down miR-34c in HCT-116 cells following 24 h-exposure to Res compared with inhibitor-NC. * P < 0.05 (d) Res-decreased KITLG
protein was recovered in the presence of miR-34c inhibitor in HCT-116 cells; while inhibitor-NC had no effect. e Res-refrained proliferation,
migration and invasion were reversed in HCT-116 cells in the presence of miR-34c inhibitor. Arrows denotes the time when miR-34c
inhibitor or inhibitor-NC was added into the medium. f Res elevated miR-28 and miR-34a levels in HCT-116 cells; while other microRNAs
remained stable. ** P < 0.01 (g) Res did not alter the target genes of the selected microRNAs in HCT-116 cells
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way. However, Res increased p53 protein in p53+ HT-29
cells (Fig. 3b), and the inducement of miR-34c by Res
was more prominent in HT-29 cells than that in p53−
HCT-116 cells (Fig. 2a), suggesting an involvement of
p53 in the Res-induced miR-34c in CRC cells. Liu et al.
[28] recently stated that Res inhibited CRC cell prolifera-
tion through restraining PI3K/Akt signaling that is
involved in p53 degradation. In our study, the phosphor-
ylation of Akt was also attenuated by 24 or 48 h-Res
treatment, which was, however, only observed in p53+
HT-29 cells (Fig. 3c).
Res sensitizes CRC cells to Oxa by up-regulating miR-34c
Oxa has been widely used in treating CRC patients.
Consistent with previous studies, our result showed that
Oxa significantly inhibited CRC cell viability in a dose
dependent manner (P < 0.05 ~ 0.001, Fig. 4a). To explore
whether there was a synergism of Oxa and Res, the CRC
cells were treated with Res and Oxa concurrently for 24
h. Res induced potentiation of cell viability inhibition
mediated by Oxa as indicated by CI analysis (CI = 0.66
in HT-29 cells and 0.27 in HCT-116 cells) (P < 0.01 or
0.001, Fig. 4b), suggesting that Res have synergistic anti-
CRC effect with Oxa.
Next, we wished to find out the underlying mechanism
of the synergistic anti-CRC effect of Res and Oxa. Since
Res markedly increased miR-34c in CRC cells, we pre-
sumed that the up-regulated miR-34c could be a potential
contributor. Therefore, we over-expressed miR-34c in
HCT-116 cells by lentivirus. Upon the treatment with Oxa
for 48 h, the viability of HCT-116 cells overexpressing
miR-34c was significantly decreased compared with con-
trols (P < 0.05, Fig. 4c). The result provided evidence that
Res sensitized the CRC cells to Oxa chemotherapy prob-
ably through up-regulating miR-34c.
In vivo anti-CRC effect of Res
To qualify the anti-CRC efficacy of Res in vivo, we per-
formed HCT-116 xenograft experiment in BALB/c nude
mice. As shown in Fig. 5a and Additional file 3: Figure
S3, Res or Oxa alone significantly inhibited tumor
growth (P < 0.05); and the co-treatment of Res and Oxa
elicited a clearly additive effect, indicated by the much
slower tumor growth compared with Res or Oxa alone,
respectively (P < 0.05). It was noted that 3 out of 7 xeno-
grafts vanished during the treatment of Res and Oxa.
Since DMSO has chronic toxicity for animal, we mea-
sured the body weight during the animal experiment.
The body weight of mice in the 4 groups did not signifi-
cantly changed during experiment (Additional file 4:
Figure S4). We further detected microRNA profile in
xenograft tumors and/or serum; and the results showed
only miR-34c was clearly elevated in tumors but not in
serum after exposure to Res for 2 weeks, indicating that
Res had a relatively specific effect on miR-34c expression
in vivo (P < 0.01, Fig. 5b). Simultaneously, KITLG was
down-regulated in xenografts of Res-treated mice
(Fig. 5c). Interleukin-6 (IL-6) and tumor necrosis factor-
α (TNF-α) are important proinflammatory cytokines
produced by inflammatory cells as well as tumor cells.
Clinical data revealed that IL-6 and TNF-α acted as
growth factors and were associated with increased risk
and advanced stages of CRC [29–32]. Our in vivo study
displayed that Res decreased IL-6 secretion in tumors (P
< 0.05) while TNF-α remained unchanged (Fig. 5d).
Discussion
Res has been of interest in oncotherapies because of its
potent anti-tumor activities and minimal side effects. To
better understand the underlying mechanism of Res in
treating CRC, we conducted in vitro and in vivo
Fig. 3 a The methylation state in the miR-34c promoter of CRC cell was not altered in the presence or absence of Res. U: unmethylation, M:
methylation (b) Res promoted p53 expression. c Res inhibited phosphorylation of Akt in p53+ HT-29 cells
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experiments. Consistent with previous reports, Res re-
pressed CRC cell viability, proliferation, capacity of
forming colonies, migration and invasion, as well as in-
duced cell cycle arrest and apoptosis. Note that, Res
arrested HCT-116 cells in G0/G1 phase while HT-29
cells in G2/M phase, indicating that the effect of Res on
the cell cycle arrest was cell type dependent. The most
interesting result was that the anti-CRC effect of Res
was partially through up-regulating the tumor suppress-
ing microRNA, miR-34c, which silenced its target
KITLG. Besides miR-34c, previous studies showed that
Res could increase some tumor suppressing microRNAs
in CRC. Namely, Res increased miR-663 that targeted
TGF-β and potentiated the anti-CRC effect of Res [13].
MiR-129 was suggested to participate in the anti-CRC
action of piceatannol, a naturally occurring analog of
Res, by targeting Bcl-2 [33]. Nevertheless, though we did
detect significant increases of tumor suppressing micro-
RNAs, miR-28 and miR-34a, their respective targets,
HoxB3 and KIT, were not decreased, implying that miR-
28-HoxB3 and miR-34a-KIT axes may not involve in the
anti-CRC activities of Res. But we could not exclude the
involvement of miR-28 and miR-34a since they may po-
tentiate the anti-CRC effect of Res by silencing other
undetermined targets which we did not detect in this
study. Fortunately, miRNA microarrays showed that Res
treatment in SW480 CRC cells significantly decreased
miR-17, miR-21, miR-25, miR-92a-2, miR-103-1 and
miR-103-2 which have been shown to behave as onco-
miRNAs [13]. Here, we also showed that Res did not up-
regulate oncogenic miR-9 and miR-19a in HCT-116
cells. It was thus inferred that the modulation of Res on
the microRNA expressions was distinct: positive on
tumor suppressing microRNAs and negative on onco-
genic microRNAs. However, the reasons for the distinct
effects of Res have been veiled yet. Taken together, we
proposed that Res had a robust positive effect on miR-
34c-KITLG axis in CRC cells and the effect was, to some
extent, specific.
It’s acknowledged that the promoter of miR-34c is
hypermethylated in CRC tissues and cell lines which
lead to silencing of miR-34c [27]. Therefore, we con-
sidered Res-induced demethylation might be respon-
sible for the increased miR-34c. However, we did not
observe any demethylated bands by MSP method
upon the treatment of Res, indicating demethylation
did not account for the Res-induced miR-34c. P53 is
a tumor suppressor and drives miR-34c transcript
[27]. Could p53 conduced to the Res-stimulated miR-
34c expression in CRC cells? Res increased miR-34c
expression both in p53+ and p53− CRC cells, suggest-
ing the effect of Res on miR-34c expression was p53
Fig. 4 a Twenty-four hr-Oxa treatment evidently inhibited CRC cell viability detected with CCK8 in a dose-dependent manner (0.5 ~ 64 μМ). * P < 0.05,
** P < 0.01, *** P < 0.001 (b) Co-treatment with Res and Oxa elicited significant synergic effects on CRC viability inhibition, according to the CI values
which was < 1. ** P < 0.01, *** P < 0.001 (c) Cell viability was deeply weaker in HCT-116 cells overexpressing miR-34c compared with controls in the
presence of 2 μM Oxa. * P < 0.05
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independent. However, it was worth noting that p53
was elevated after treated with Res in HT-29 cells
and, simultaneously, the inducement of miR-34c by
Res was more prominent in HT-29 cells, indicating
p53 facilitated the effect of Res on miR-34c expres-
sion. We also found inactivation of PI3K/Akt signal-
ing upon the treatment of Res only in HT-29 cells,
which possibly account for the up-regulation of p53
by inhibiting MDM2, a ubiquitin protein ligase con-
trolling the degradation of p53. A recent work pro-
vided a new evidence that Res can bind directly and
distinctively to miR-33a and miR-122 and divergently
modulate their levels in hepatic cells [34]. Whether
the increase of miR-34c in CRC was due to the
stabilization of Res deserves deep investigation. If so,
we hope to find out the underlying mechanism of the
distinct effects of Res on the oncogenetic microRNAs
and tumor suppressing microRNAs.
Oxa is one of the first choices treating CRC patients
currently; but the side effects and drug resistance caused
by the long-term use interfere with the therapeutic effi-
ciency. In this study, Res was introduced to facilitate the
chemosensitivity to Oxa in CRC cells, which was prob-
ably relied on the elevated miR-34c. Moreover, no publi-
cations showed that Res was harmful to patients,
suggesting Res could be a safe medication in preventing
CRC. Lines of evidence suggested Res reversed
multidrug resistance by down-regulating MDR-1 gene in
breast cancer cells [35, 36]. Wen et al. [37] addressed
that PI3K/Akt signaling positively regulated MDR-1 in
CRC. According to the previous and present results, we
presumed that Res-induced miR-34c in CRC cells might
be associated with the reduced MDR-1 or other multi-
drug resistance-related genes via silencing PI3K/Akt
pathway, which, however, needs further investigation.
The in vivo xenograft experiment further consolidated
the in vitro results. Res raised the miR-34c expression in
tumors but not in serum, giving a clue that the miR-34c-
inducing effect of Res was tissue specific instead of sys-
temic. Moreover, the proinflammatory cytokine IL-6 was
reduced exposure to the 2-week Res treatment. IL-6 could
act as growth factor in multiple tumors by activating the
oncogenic STAT3 transcription factor. Rokavec et al. [38]
identified that miR-34a/c could target IL-6R by binding to
its 3′ untranslated region (3′UTR); thereby disrupted the
IL-6/IL-6R-STAT3-miR-34a loop. Here, we hypothesized
that the IL-6-triggered CRC progression could be inter-
fered by the Res-increased miR-34c.
Conclusion
In summary, the present study revealed that Res inhib-
ited CRC by activating miR-34c-KITLG in vitro and in
vivo; and the effect was strengthened in the presence of
Fig. 5 a Res or Oxa could significantly restrict the xenograft growth and the effect was overtly enhanced when co-treated with Res and Oxa. b
Res increased miR-34c in tumors but not in serum. MiR-214 was also increased in tumors after Res treatment. ** P < 0.01 (c) KITLG was apparently
reduced in tumors of Res-treated mice. d IL-6 in tumors was diminished while TNF-α stayed unvarying
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p53. In addition, the up-regulated miR-34c by Res sensi-
tized chemosensitivity to Oxa treatment in CRC cells.
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